TrialThe lancet. HIV2025

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.

Kelly E Seaton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.